Skip to main content
NewslettersWatchlist

Small Pharma Inc(DMTTF)
OTC US

Today's Change
Delayed Last Update
Day Low0.1051
Day High0.1325
Open:0.1125
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Small Pharma Reports Fiscal Second Quarter 2024 Highlights
GlobeNewswire
Small Pharma Announces Voting Results from Annual General and Special Meeting of Shareholders
GlobeNewswire
Disposition of Common Shares of Small Pharma Inc.
GlobeNewswire
Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
Newsfile
Cybin to Acquire Small Pharma Inc.
GlobeNewswire
Small Pharma Reports Fiscal First Quarter 2024 Highlights
GlobeNewswire
Small Pharma Announces SPL028 R&D Strategy Update
GlobeNewswire
Small Pharma Announces Management Team Change
GlobeNewswire
Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights
PressReach
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
Globe Newswire
Canadian Patent Grant Strengthens Small Pharma’s International Position
Globe Newswire
U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation
Globe Newswire
George Tziras to Succeed Peter Rands as Small Pharma Chief Executive Officer
Globe Newswire
Small Pharma Reports Fiscal First Quarter 2023 Highlights
Globe Newswire
Small Pharma to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
Globe Newswire
Small Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022
Globe Newswire
Small Pharma To Present at the Jefferies Healthcare Conference in New York City on June 10, 2022
Globe Newswire
Small Pharma Shares Business Update Ahead of Annual Financial Results
Globe Newswire
Small Pharma to Participate in the PSYCH Symposium: London 2022
Globe Newswire
Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets
Globe Newswire
Small Pharma to Participate in the 34th Annual Roth Conference
Globe Newswire
World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
Globe Newswire
Small Pharma Reports Fiscal Third Quarter 2021 Highlights
Globe Newswire
Small Pharma to Attend Upcoming Healthcare Conferences in January 2022
Globe Newswire
Small Pharma to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6, 2021
Globe Newswire
Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director
Globe Newswire
Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder
Globe Newswire
Small Pharma to Attend Upcoming Healthcare Conferences in November 2021
Globe Newswire
Small Pharma Reports Second Quarter Highlights
Globe Newswire
European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive Disorders
Globe Newswire
Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder
Globe Newswire
Small Pharma Announces Upgrade to the OTCQB® and DTC Eligibility

Profile

N/A

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.